Epidermal growth factor (EGF) 
Introduction
Epidermal growth factor (EGF)' is a 6,000-D peptide first purified from mouse submandibular glands (SMG) (1) . The human counterpart of EGF, urogastrone, was isolated from urine and named for its ability to inhibit gastric acid secretion (2) . EGF acts as a mitogen or progression factor for mitosis in a variety of cell lines, and has important developmental effects (3, 4) . It promotes eyelid opening, palate development, tooth eruption, and gut development in rodents; it is important in the maturation and function of hair follicles in several species; and lung maturation and alveolarization are promoted by EGF in the sheep (3) (4) (5) (6) . EGF and EGF receptors have been identified in fetal rodent tissues and a role for EGF in fetal development has been 1 . Abbreviations used in this paper: ANOVA, analysis of variance; AVP, arginine vasopressin; CRF, corticotropin-releasing factor, E, epinephrine; EGF, epidermal growth factor, CH, growth hormone; NE, norepinephrine; oCRF, ovine CRF; POMC, proopiomelanocortin; SMG, submandibular glands.
proposed (5, 7) . Significant levels of EGF are found in human amniotic fluid (8) .
Hormone-EGF interactions have been reported and it has been proposed that EGF may mediate the developmental effects of selected hormones (9) . EGF production in mouse SMG is thyroxine and testosterone responsive and urine EGF production and kidney EGF concentrations are thyroxine responsive in the mouse (10) (11) (12) . EGF concentrations in several other tissues including liver, skin, and eye also are thyroxine responsive (13, 14) as is EGF receptor binding in skin and liver (15, 16) . Finally, EGF has been shown to evoke hormone secretion from cultured anterior pituitary cells (17) (18) (19) , and a recent paper reports that EGF augments ACTH release in vivo in adult sheep (20).
The circulating levels of anterior pituitary hormones, particularly ACTH, growth hormone (GH), and gonadotropins are markedly elevated in the mammalian fetus during the latter half of gestation (21) . These high levels presumably are due to relatively high rates of secretion, but the mechanism(s) remain obscure (21 duplicate. Fetal heart rate, arterial blood pressure, and arterial blood gases were measured at each sampling time. Materials. EGF was purified to homogeneity from adult Swiss Webster mice as reported previously (14, 22). The final product migrated as a single band by polyacrylamide gel electrophoresis and had an apparent molecular mass approximating 6,000 D. oCRF, synthesized using solid phase techniques, was purchased commercially (Bachem Co., Torrance, CA) and used for injection and for development of the radioimmunoassay.
Hormone assays. ACTH was determined by radioimmunoassay (RIA) in EDTA plasma using a second antibody-polyethylene glycol procedure after QUSO extraction (North America Silica Co., Teterboro, NJ) at the Nichols Institute, San Juan Capistrano, CA (23). The antiserum (from Dr. Donald West, University of Utah School of Medicine) was used in a final dilution of 1:75,000 (23); ACTH from Bachem Co. was labeled with 12"I using the chloramine T method (24) , and the labeled hormone was purified by HPLC. The same Bachem material was used as standard in the RIA. Intraassay and interassay coefficients ofvariation were 9 and 13.2%, respectively. Sensitivity of the assay was 8 pg/ml (at 90% B/Bo).
Arginine vasopressin was determined in plasma after Sep-Pac C18 cartridge (Waters Associates, Milford, MA) elution using our previously described RIA (25). The sensitivity of this assay was I pg/ml. Epinephrine (E) and norepinephrine (NE) were determined in EGTA/GSH plasma by radioenzymatic assay with a sensitivity approximating 2 pg/ml (26) . Growth hormone was measured by RIA using material generously provided by the National Institute ofArthritis, Diabetes, Digestive and Kidney diseases. Sensitivity of this assay was 100 pg/ml. rate, arterial blood pressure, and arterial blood gas values were unchanged during the study (Table I) .
Plasma AVP, E, NE, and GH concentrations from the salineand EGF-treated animals are shown in Table II . Baseline AVP (Fig. 2) . When compared on a molar basis, EGF is a more potent CRE than synthetic CRF at dosages < 1 nmol. However, at the highest dosages used in this study (20 Mug or the equivalent of 3.2 nmol of EGF and 4 nmol of CRF), CRF administration is associated with nearly three times the plasma ACTH immunoreactivity when compared with EGF administration (Fig. 2) . The mechanisms for these differences are not clear but may represent additional effects of CRF on AVP release, resulting in augmented ACTH responses. Our purified mouse EGF shows no crossreactivity with our anti-oCRF antiserum and does not increase circulating immunoreactive oCRF concentrations to measurable levels in the RIA. By contrast, plasma oCRF immunoreactivity increased to a level of6.1 ng/ml after the injection of 10 Mg of oCRF (Table III) . These data suggest that EGF is not acting to provoke CRF release, although an effect on hypothalamic CRF release to increase pituitary portal blood CRF without altering peripheral levels is possible; we did not measure endogenous pituitary portal blood oCRF concentrations in the present study. Neither did EGF stimulate AVP or catecholamine release measurable in peripheral blood (Table II) . These results support the hypothesis that EGF may -stimulate ACTH release via a direct action on anterior pituitary corticotrophic cells.
Circulating EGF levels after injection of EGF were not determined, but circulating levels of oCRF 30 min after a 10-,g injection ofsynthetic oCRF were 6.1 ± 1 ug/ml (Table III) . Ifthe plasma levels of EGF attained after a 10-,gg dose of EGF were similar, then the EGF levels would approximate plasma levels ofEGF that have been reported in humans and rodents (4) . This lends further support that these low levels of circulating EGF may have physiologic significance. The oCRF peptide is comprised of 41 amino acid residues and differs from human and rat CRF by seven residues (27) . Human, rat and ovine CRF share primary sequences with several nonmammalian peptides, notably sauvagine and urotensin I, and demonstrate some homology with calmodulin and angiotensinogen (27) . The tetrapeptide Phe-His-Leu-Leu is common to both angiotensinogen and CRF and this sequence is the site of renin and converting enzyme cleavage (27) . Comparison of CRF, sauvagine, and urotensin I suggests that the double leucine residues at positions 14-15 and 37-38 and the basic groups at 16 and 35 are critical in preserving the ACTH releasing potencies of these peptides. Conformationally, an a-helix for residues 5-30 and a ,8-bend encompassing residues 31-35 is predicted (27) .
This structure contrasts with that of EGF as defined by nuclear magnetic resonance; this protein shows a predominantly #-structure with little or no a-helicity (30) . EGF, a single polypeptide chain of53 amino acid residues containing three disulfide bands, demonstrates 32% homology with a-transforming growth factor, and these two substances probably bind to a similar receptor site in the target cell membrane (31, 32). EGF also has been reported to have 8-10% similarity in primary structure to the secretin family of peptides (gastric inhibiting peptide, glucagon, and vasoactive intestinal peptide), as well as pancreatic secretory trypsin inhibitor (33). These similarities may account for the EGF effect on gastric acid secretion. Thus, there are no homologous domains for EGF or CRF, and primary, secondary, or tertiary structural similarities would seem an unlikely explanation for the CRF-like effects of EGF.
EGF receptors are demonstrable in a number of cell lines and organs. Fetal animal studies show that liver and carcass (including skin) bind the highest amounts of EGF and that receptors are present early in gestation during the trophoblastic stage in the mouse (34 It is possible that the ACTH response demonstrated in the current study occurred independently of a change in pituitary ACTH release. The human placenta, in addition to being a source of extrahypothalamic peptides such as gonadotropin releasing hormone, thyrotropin releasing hormone, somatotropin releasing inhibiting factor, corticotropin releasing factor, and growth hormone releasing factor, also may synthesize a proopiomelanocortin (POMC)-like substance (39, 40) . In women, the nonsuppressibility of maternal plasma ACTH levels near term has suggested a placental source of ACTH (41) . However, the control of "chorionic ACTH" production is unknown. In the mouse, the developing trophoblast contains large numbers ofhigh affinity EGF receptors (34) . Thus, an effect ofEGF on chorionic POMC metabolism and ACTH production is possible.
In summary, we have demonstrated that administration of EGF to near term, chronically catheterized, ovine fetuses is associated with an increase in circulating immunoreactive ACTH concentrations. We were unable to demonstrate a change in circulating CRF, AVP or catecholamine levels in response to the EGF infusions, and dose response curves suggest that EGF is as potent a corticotropin releasing factor as synthetic oCRF at low doses. We speculate that EGF may be important in the regulation of pituitary function in developing ovine fetuses.
